nicorandil ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
nicotinic acid or nicotinoyl alcohol derivatives 1919 65141-46-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicorandil
  • perisalol
  • sigmart
A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.
  • Molecular weight: 211.18
  • Formula: C8H9N3O4
  • CLOGP: 0.54
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 97.04
  • ALOGS: -2.25
  • ROTB: 5

Drug dosage:

DoseUnitRoute
40 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 4.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.06 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 75 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.40 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.76 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1984 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 63.42 23.86 73 2967 227985 50374099
Cardiac failure 51.57 23.86 40 3000 76000 50526084
Fixed eruption 48.31 23.86 11 3029 828 50601256
Hyponatraemia 43.38 23.86 40 3000 96099 50505985
Upper gastrointestinal haemorrhage 35.71 23.86 18 3022 16017 50586067
Bradycardia 35.42 23.86 30 3010 64396 50537688
Hypotension 32.75 23.86 54 2986 235415 50366669
Drug interaction 32.19 23.86 49 2991 199572 50402512
Rhabdomyolysis 31.93 23.86 23 3017 39004 50563080
Wrong patient 29.16 23.86 5 3035 85 50601999
Drug ineffective 28.86 23.86 7 3033 819326 49782758
Large intestinal ulcer 26.19 23.86 9 3031 3060 50599024
Hyperkalaemia 25.61 23.86 22 3018 48067 50554017
Haemorrhage intracranial 24.97 23.86 13 3027 12361 50589723
Ischaemic stroke 24.53 23.86 14 3026 15934 50586150

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Interstitial lung disease 57.17 20.24 60 5124 57658 29511685
Postictal paralysis 44.64 20.24 10 5174 233 29569110
Angina pectoris 42.92 20.24 37 5147 27813 29541530
Acute kidney injury 40.80 20.24 120 5064 265147 29304196
Intraventricular haemorrhage 32.92 20.24 14 5170 2892 29566451
Drug interaction 32.89 20.24 92 5092 197293 29372050
Melaena 31.88 20.24 33 5151 31143 29538200
Muscle haemorrhage 27.82 20.24 13 5171 3349 29565994
Cardiac failure 26.76 20.24 49 5135 79238 29490105
Pericardial haemorrhage 26.34 20.24 12 5172 2919 29566424
Altered state of consciousness 25.83 20.24 24 5160 19865 29549478
Cerebral infarction 25.01 20.24 26 5158 24649 29544694
Prerenal failure 24.95 20.24 10 5174 1778 29567565
Hypomagnesaemia 24.48 20.24 22 5162 17446 29551897
Lactic acidosis 23.95 20.24 28 5156 30219 29539124
Hypovitaminosis 23.90 20.24 7 5177 483 29568860
Coagulation factor deficiency 23.87 20.24 5 5179 84 29569259
Chest pain 23.53 20.24 57 5127 111916 29457427
Bradycardia 22.70 20.24 41 5143 65588 29503755
Coronary artery restenosis 22.58 20.24 8 5176 1014 29568329
Pulmonary alveolar haemorrhage 22.52 20.24 14 5170 6366 29562977
Swollen tongue 22.42 20.24 18 5166 12248 29557095
Muscle contractions involuntary 21.84 20.24 9 5175 1718 29567625
Cardiorenal syndrome 21.57 20.24 7 5177 679 29568664
Malaise 20.53 20.24 68 5116 159534 29409809
Haemoptysis 20.48 20.24 26 5158 30524 29538819
Labelled drug-drug interaction medication error 20.45 20.24 17 5167 12142 29557201

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 93.47 19.21 192 8351 449048 64041141
Interstitial lung disease 68.17 19.21 74 8469 97658 64392531
Cardiac failure 65.40 19.21 84 8459 132289 64357900
Drug interaction 65.06 19.21 146 8397 361937 64128252
Angina pectoris 64.48 19.21 51 8492 45030 64445159
Hyponatraemia 59.40 19.21 85 8458 148254 64341935
Bradycardia 50.66 19.21 70 8473 118149 64372040
Upper gastrointestinal haemorrhage 48.55 19.21 39 8504 35181 64455008
Cerebral infarction 47.35 19.21 41 8502 41003 64449186
Melaena 45.32 19.21 45 8498 53503 64436686
Postictal paralysis 43.88 19.21 10 8533 337 64489852
Ischaemic stroke 39.69 19.21 32 8511 29003 64461186
Hypomagnesaemia 38.46 19.21 35 8508 37341 64452848
Drug ineffective 37.33 19.21 34 8509 840213 63649976
Hypotension 36.47 19.21 122 8421 380852 64109337
Renal impairment 33.08 19.21 62 8481 134955 64355234
Cerebral haemorrhage 32.68 19.21 37 8506 51053 64439136
Hepatic function abnormal 32.01 19.21 41 8502 64272 64425917
Intraventricular haemorrhage 31.88 19.21 14 8529 4139 64486050
Gastric ulcer 30.49 19.21 28 8515 30206 64459983
Pneumonia aspiration 29.83 19.21 38 8505 59233 64430956
Fixed eruption 29.44 19.21 11 8532 2148 64488041
Acute myocardial infarction 29.41 19.21 41 8502 69677 64420512
Hyperkalaemia 28.02 19.21 49 8494 101080 64389109
Muscle haemorrhage 27.52 19.21 14 8529 5739 64484450
Haemorrhage intracranial 25.81 19.21 23 8520 23861 64466328
Pericardial haemorrhage 25.60 19.21 12 8531 4124 64486065
Pulmonary alveolar haemorrhage 25.59 19.21 16 8527 9722 64480467
Gastrointestinal haemorrhage 25.51 19.21 55 8488 132257 64357932
Blood pressure decreased 25.50 19.21 43 8500 86156 64404033
Lip swelling 25.49 19.21 26 8517 31881 64458308
Prerenal failure 25.18 19.21 11 8532 3211 64486978
Altered state of consciousness 25.18 19.21 28 8515 37874 64452315
Coagulation factor deficiency 25.04 19.21 5 8538 88 64490101
Chest pain 24.72 19.21 78 8465 235902 64254287
Pain 23.80 19.21 23 8520 553488 63936701
Pemphigoid 23.68 19.21 17 8526 12969 64477220
Coronary artery restenosis 22.87 19.21 8 8535 1294 64488895
Prinzmetal angina 21.75 19.21 8 8535 1495 64488694
Hypovitaminosis 21.72 19.21 7 8536 881 64489308
Wrong patient 21.38 19.21 5 8538 189 64490000
Electrocardiogram QT prolonged 21.36 19.21 38 8505 79410 64410779
Rhabdomyolysis 21.07 19.21 41 8502 91685 64398504
Pancytopenia 20.47 19.21 53 8490 143256 64346933
Malaise 19.77 19.21 104 8439 396143 64094046
Acute coronary syndrome 19.70 19.21 18 8525 19292 64470897
Labelled drug-drug interaction medication error 19.51 19.21 19 8524 22043 64468146
Large intestinal ulcer 19.47 19.21 10 8533 4183 64486006
Haemoptysis 19.43 19.21 28 8515 49020 64441169
Cardiorenal syndrome 19.38 19.21 7 8536 1243 64488946
Immune thrombocytopenia 19.31 19.21 16 8527 15050 64475139

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01DX16 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
VASODILATORS USED IN CARDIAC DISEASES
Other vasodilators used in cardiac diseases
CHEBI has role CHEBI:35620 vasodilator agents
CHEBI has role CHEBI:79085 potassium channel agonist
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018977 Micronutrients
MeSH PA D014665 Vasodilator Agents
MeSH PA D014803 Vitamin B Complex
MeSH PA D014815 Vitamins

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Angina pectoris indication 194828000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.97 acidic
pKa2 3.07 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
ATP-sensitive inward rectifier potassium channel 11 Ion channel IC50 5.89 WOMBAT-PK
ATP-sensitive inward rectifier potassium channel 1 Ion channel IC50 5.95 WOMBAT-PK
Atrial natriuretic peptide receptor 1 Enzyme EC50 7.20 WOMBAT-PK

External reference:

IDSource
N0000167327 NUI
D01810 KEGG_DRUG
C0068700 UMLSCUI
CHEBI:31905 CHEBI
CHEMBL284906 ChEMBL_ID
DB09220 DRUGBANK_ID
D020108 MESH_DESCRIPTOR_UI
47528 PUBCHEM_CID
4933 INN_ID
2411 IUPHAR_LIGAND_ID
260456HAM0 UNII
31748 RXNORM
005831 NDDF
319304004 SNOMEDCT_US
395809002 SNOMEDCT_US

Pharmaceutical products:

None